Arcturus Therapeutics Holdings Inc.
ARCT
$6.65
$0.060.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.15% | -25.47% | 15.38% | -8.69% | -45.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.15% | -25.47% | 15.38% | -8.69% | -45.85% |
| Cost of Revenue | -27.19% | -43.66% | -2.26% | 12.02% | 14.74% |
| Gross Profit | -295.94% | 126.27% | 109.48% | -134.36% | -95.61% |
| SG&A Expenses | -16.09% | -10.82% | -8.66% | -0.09% | 1.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.98% | -23.04% | -8.93% | 1.21% | 2.65% |
| Operating Income | 2.73% | 18.57% | 33.47% | -22.33% | -230.93% |
| Income Before Tax | -6.94% | 14.46% | 34.82% | -190.23% | -161.04% |
| Income Tax Expenses | -100.00% | -115.80% | -117.67% | -100.16% | -90.83% |
| Earnings from Continuing Operations | -6.49% | 16.39% | 36.44% | -172.30% | -163.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.49% | 16.39% | 36.44% | -172.30% | -163.07% |
| EBIT | 2.73% | 18.57% | 33.47% | -22.33% | -230.93% |
| EBITDA | 2.36% | 19.15% | 34.51% | -22.43% | -219.93% |
| EPS Basic | -5.70% | 17.20% | 37.31% | -168.80% | -162.16% |
| Normalized Basic EPS | -6.15% | 15.28% | 35.71% | -29.06% | -189.99% |
| EPS Diluted | -5.62% | 17.23% | 37.31% | -158.58% | -164.50% |
| Normalized Diluted EPS | -6.15% | 15.28% | 35.71% | -28.28% | -193.95% |
| Average Basic Shares Outstanding | 0.83% | 1.17% | 1.40% | 1.49% | 1.26% |
| Average Diluted Shares Outstanding | 0.83% | 1.17% | 1.40% | 0.93% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |